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ABSTRACT
This study evaluated the possible changes in antibiotic use that might follow the implementation of
British or North American guidelines for the treatment of community-acquired pneumonia (CAP) in The
Netherlands. Patients admitted for mild, moderate and severe CAP were evaluated prospectively.
Volume of antibiotic use, based upon guidelines of the British Thoracic Society (BTS), the Infectious
Diseases Society of America (IDSA) or the American Thoracic Society (ATS), was estimated and
compared to current practice. For 248 patients, current antibiotic use was 3087 deﬁned daily doses.
Antibiotic use would increase by 38% if based on ATS guidelines, by 23% if based on IDSA guidelines,
and by 21% if based on BTS guidelines. The most signiﬁcant increase in antibiotic use would occur for
cases of moderate CAP, with incremental antibiotic costs of 1 750 000–3 500 000 Euros in The
Netherlands.
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INTRODUCTION
Community-acquired pneumonia (CAP) is a com-
mon disease that is associated with considerable
mortality and morbidity, and that accounts for
high antibiotic consumption [1,2]. Ideally, initial
antibiotic therapy for CAP is targeted at the
causative microorganism, but as this cannot be
determined on the basis of clinical, laboratory and
radiographic ﬁndings, initial therapy is invariably
empirical [3–5]. Streptococcus pneumoniae is the
pathogen isolated most commonly [6–8]. For-
merly, the recommended empirical therapy for
uncomplicated pneumonia was benzylpenicillin,
amoxycillin or another b-lactam antibiotic. The
addition of a macrolide or a quinolone to the
initial treatment was not recommended unless
there was a strong suspicion of atypical pneu-
monia, based on clinical history or laboratory
ﬁndings, or if there was severe pneumonia requi-
ring mechanical ventilation [9–11]. Although con-
troversies remain regarding the design of the
studies forming the basis of the latest recommen-
dations, British and North American infectious
diseases and thoracic societies now recommend
initial therapy with combinations of b-lactams
and macrolides, or monotherapy with quinolones,
for patients hospitalised because of CAP [12–16].
Other European, including Dutch, guidelines still
recommend b-lactam monotherapy as initial man-
agement for CAP patients treated in general
wards [17–19].
Currently, new treatment guidelines for CAP in
The Netherlands are under consideration. If a
strategy for treating CAP patients with combina-
tions of b-lactams and macrolides or monotherapy
with ﬂuoroquinolones is introduced in The Neth-
erlands, this will clearly affect antibiotic use. The
possible adverse consequences of an increase in
antibiotic use include an increase in drug costs, a
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possible increase in side-effects related to antibi-
otic treatment, and an increase in selection pres-
sure that enhances the development of resistance
[20]. Favourable effects may include an increase
in adequate treatment and an improvement in
clinical outcomes. Therefore, this study estimated
the changes in antibiotic use and antibiotic-related
costs that might result in The Netherlands from
the initial treatment of CAP according to the
guidelines of the British Thoracic Society (BTS),
the Infectious Diseases Society of America (IDSA)
or the American Thoracic Society (ATS).
MATERIALS AND METHODS
Patients
Consecutive episodes of CAP in patients admitted to the
University Medical Center, Utrecht, The Netherlands between
September 2000 and January 2003 were evaluated in a
prospective observational study. CAP was deﬁned as a new
or progressive inﬁltrate on chest X-ray, combined with two or
more of the following criteria: cough, production of purulent
sputum, rectal temperature > 38C or < 36C, auscultatory
ﬁndings consistent with pneumonia, leukocytosis
(> 10 000 ⁄mm3) or C-reactive protein level > three-fold above
the normal upper limit [21]. Patients with cystic ﬁbrosis,
neutropenic patients (< 0.5 · 109 neutrophils ⁄L) and patients
with another infection that required treatment were excluded
from the analysis. Patients were placed into three categories:
mild CAP was deﬁned as Fine class I–III; moderate CAP was
deﬁned as Fine class IV or V, or fulﬁlling the ATS criteria for
severe CAP, but not treated in the intensive care unit (ICU);
and severe CAP was deﬁned as treated in the ICU. Demogra-
phic and clinical data were collected. Initial antibiotic therapy
was deﬁned as antibiotic therapy instituted within 24 h of
admission. In addition, points were assigned according to BTS
guidelines for the presence of confusion, urea > 7 mmol ⁄L,
respiratory rate > 30 ⁄min, and systolic blood pressure
< 90 mm Hg or diastolic blood pressure < 60 mm Hg. For the
presence of each feature, one point was assigned (CURB
classiﬁcation) [16]. For calculation of risk classiﬁcation, the ﬁrst
X-ray, blood gas measurements, etc. were used. If values were
not noted, the risks were considered not to be present.
Microbiology
Microbiological examination of sputum and blood samples
was performed according to standard procedures at the
request of the treating physician. Microorganisms cultured
from blood or sputum were recorded. In addition, NOW tests
(Binax, Portland, MS, USA) were used to detect urinary
antigen for Legionella pneumophila and S. pneumoniae. Collected
acute and convalescent sera were evaluated for Mycoplasma
pneumoniae, L. pneumophila and Chlamydia pneumoniae.
Any non-contaminating microorganism cultured from a
blood or sputum sample, or detected by urinary antigen
testing, was considered to be a cause of the episode of
pneumonia. For M. pneumoniae, a four-fold or greater increase
in titre in paired sera, or a single titre ‡ 1:40 (immune
ﬂuorescence agglutination; Serodia-MycoII, Fujirebio Diagnos-
tics, Malvern, PA, USA), was considered to be indicative of
infection [22]. For L. pneumophila, a four-fold increase in the
antibody titre to ‡ 1:128, or single titres of ‡ 1:256, were
considered to be evidence of Legionella pneumonia [23]. For
C. pneumoniae, detection of IgM above established values,
seroconversion of IgG between acute and convalescence
samples, high amounts of IgG in single titres, or a combination
of these factors (ELISA; Savyon Diagnostics, Ashdod, Israel),
were considered to be serological evidence of infection.
Antibiotic use
Empirical antibiotic treatment was according to Dutch guide-
lines [17], i.e., monotherapy with a b-lactam as initial therapy,
unless CAP caused by M. pneumoniae, C. pneumoniae or L.
pneumophila was suspected, or in the case of severe CAP.
Comparisons were made between current antibiotic use and
predicted treatment based on the BTS guidelines (CURB
classiﬁcations), IDSA guidelines, and ATS guidelines
[12,15,16]. In the calculations based on CURB classiﬁcation,
patients assigned none or one CURB point without additional
features (age > 50 years, presence of co-morbid illness, satura-
tion< 92%, or bilateral inﬁltrates)were givenmonotherapywith
a b-lactam. Patients with one CURB point with additional
features, and patients with ‡ 2 CURB points, were given
ceftriaxone with erythromycin. For the calculations based on
IDSA guidelines, patients in Fine classes II and III were given
b-lactam monotherapy (as outpatient therapy), while ceftriax-
one and erythromycin were given to patients in Fine classes IV
and V. For the calculations based on ATS guidelines, macrolide
monotherapy was given to patients without ATS-deﬁned
modiﬁers (age > 65 years, b-lactam therapy within the past
3 months, alcoholism, immunosuppressive illness, multiple
medical co-morbidities, exposure to a child in a day care centre,
residence in a nursing home, underlying cardiopulmonary
disease, multiple medical co-morbidities, recent antibiotic ther-
apy, structural lung disease, corticosteroid therapy, broad-
spectrum antibiotic therapy for > 7 days in the past month, or
malnutrition), while the combination of ceftriaxone and eryth-
romycin was given to patients with ATS-deﬁnedmodiﬁers [15].
Calculations were based on a standard duration of treat-
ment (3 days for azithromycin; 10 days for all other antibiot-
ics) and were expressed in deﬁned daily doses (DDDs; http://
www.whocc.no/atcddd/). Drug costs were determined using
2003 Dutch price levels, as indicated in the Dutch Pharmaco-
therapeutic Guide.
RESULTS
Patients
In total, 248 patients admitted with CAP were
included in the study (Table 1). Of these, 50 (20%)
patients were admitted to the ICU, 107 (43%)
were diagnosed with moderate CAP, and 91
(37%) were diagnosed with mild CAP. Eighty-
two (33%) patients did not fulﬁl any CURB
criteria, 35 (14%) fulﬁlled one CURB criterion
without additional features, 61 (25%) fulﬁlled one
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CURB criterion with additional features, and 70
(29%) fulﬁlled at least two CURB criteria. There
were 121 (49%) patients in Fine classes IV and V,
and 155 (63%) had ATS-deﬁned modiﬁers.
Clinical outcome
Thirty-two (13%) patients died, comprising 21
(42%) of 50 patients admitted initially to the ICU,
eight (7%) of 107 patients with moderate-to-
severe CAP, and three (3%) of 91 patients with
mild CAP. Two (2%) patients admitted initially to
a general ward deteriorated clinically and needed
mechanical ventilation in the ICU; one of these
patients died.
Microbiological outcome
The pathogen isolated most frequently was
S. pneumoniae (50 (20%) patients). As the frequency
of penicillin resistance among S. pneumoniae
isolates in The Netherlands is < 1%, all pneumo-
coccal isolates were considered to be penicillin-
susceptible for the purposes of this analysis.
Other bacteria were isolated in 73 (29%) patients.
Twenty-one (9%) patients had evidence of ‘aty-
pical’ infections; i.e., two patients admitted to the
ICU had CAP caused by L. pneumophila, 14
patients with moderate CAP had atypical infec-
tion (M. pneumoniae, n = 1; C. pneumoniae, n = 11;
L. pneumophila, n = 2), and ﬁve patients with mild
CAP had atypical infection (M. pneumoniae, n = 1;
C. pneumoniae, n = 3; L. pneumophila, n = 1). No
aetiological cause was identiﬁed for 115 (46%)
episodes of CAP (Table 2).
Antibiotic use and costs
Current antibiotic use consisted of monotherapy
with a b-lactam antibiotic in 153 (62%) patients, a
macrolide in seven (3%) patients, and a ﬂuoro-
quinolone in ﬁve (2%) patients. Eighty-ﬁve (23%)
patients received combinations of b-lactams and
macrolides, or other combinations (n = 18; 7%).
Combination therapy was prescribed more fre-
quently for patients who were admitted initially
to the ICU (42% of 50 patients in the ICU vs. 21%
and 17% for patients with mild or moderate CAP,
respectively; p < 0.01). Based on 10-day antibiotic
courses (500 mg of azithromycin once-daily for
3 days), total antibiotic consumption was
3087 DDDs. Predicted antibiotic use, based on
BTS guidelines, would increase to 3790 DDDs
(95% CI, 3645–3943), i.e., an increase of 23% (95%
CI, 17–28%). Treatment based on IDSA guidelines
Table 1. Characteristics of patients with community-
acquired pneumonia (CAP)
Total
n (% ) or
mean ± SD
Severe
CAP
Moderate
CAP
Mild
CAP
Total 248 50 (20) 107 (43) 91 (37)
Males 145 (59) 33 (66) 74 (69) 38 (42)
Age (years) 59.5 ± 18 58.8 ± 17 66.5 ± 15 51.4 ± 17
Fine 92.6 ± 36 109.4 ± 34 111.1 ± 29 61.5 ± 20
Leukocytes · 109 ⁄L 15.0 ± 7 14.3 ± 7 15.6 ± 8 14.7 ± 6
Respiratory rate ⁄min 27.2 ± 9 31.9 ± 10 28 ± 9 24.2 ± 7
In-hospital mortality 32 (13) 21 (42) 8 (8) 3 (3)
Length of stay (days) 12.4 ± 11 16.4 ± 18 10.8 ± 6 8.2 ± 4
ICU length of stay (days) – 9.7 ± 14 – –
CURB classa
0 82 (33) 9 (18) 15 (14) 58 (64)
1 35 (14) 11 (22) 6 (5) 18 (20)
1+ 61 (25) 12 (24) 41 (38) 8 (9)
2 54 (22) 15 (30) 32 (29) 7 (8)
3 14 (6) 3 (6) 11 (10)
4 2 (2) 0 (0) 2 (2)
Fine class
2 72 (29) 9 (18) 9 (8) 54 (59)
3 55 (22) 6 (12) 13 (12) 37 (41)
4 81 (32) 18 (36) 62 (58)
5 40 (16) 17 (34) 23 (22)
Initial therapy, patients
Bl 153 (62) 8 (16) 83 (78) 62 (68)
Fl 5 (2) 0 (0) 0 (0) 5 (5)
M 7 (3) 1 (2) 3 (3) 3 (3)
Bl + M 58 (23) 21 (42) 18 (17) 19 (21)
Bl + Ag 13 (5) 11 (22) 1 (1) 1 (1)
Bl + M + Ag 3 (1) 3 (6) 0 (0) 0 (0)
Other 9 (4) 6 (12) 2 (2) 1 (1)
Initial therapy (DDDs)
b-Lactams 2340 830 1050 460
Fluoroquinolones 70 50 168 270
Macrolides 602 164 0 20
Others 75 16 11 48
Total 3087 1060 1229 798
aCURB, one point each for: confusion; urea > 7 mmol ⁄L; respiratory rate > 30 ⁄min;
systolic blood pressure < 90 or diastolic blood pressure < 60 mm Hg. ‘+’ indicates
the presence of additional features such as age > 50 years, presence of co-morbid
illness, saturation < 92%, or bilateral inﬁltrates.
Bl, b-lactam; M, macrolide; Fl, ﬂuoroquinolone; Ag, aminoglycoside; ICU, intensive
care unit; DDD, deﬁned daily dose.
Table 2. Aetiology of 248 cases of community-acquired
pneumonia (n (%))
Total
(n = 248)
ICU
(n = 50)
Moderate
(n = 107)
Mild
(n = 91)
Streptococcus pneumoniae 50 (20) 14 (28) 31 (29) 5 (6)
Escherichia coli 9 (4) 3 (6) 4 (4) 2 (2)
Staphylococcus aureus 11 (4) 4 (8) 6 (6) 1 (1)
Haemophilus inﬂuenzae 6 (2) 2 (4) 2 (2) 2 (2)
Streptococcus oralis 2 (1) 2 (4) 0 0
Pseudomonas aeruginosa 5 (2) 3 (6) 0 2 (2)
Moraxella catarrhalis 6 (2) 1 (2) 3 (3) 2 (2)
Morganella morganii 4 (2) 3 (6) 0 1 (1)
Legionella pneumophila 5 (2) 2 (4) 2 (2) 1 (1)
Chlamydia pneumoniae 14 (6) 0 11 (10) 3 (3)
Mycoplasma pneumoniae 2 (1) 0 1 (1) 1 (1)
Klebsiella pneumoniae 4 (2) 2 (4) 0 2 (2)
Inﬂuenza virus 5 (2) 2 (4) 0 3 (3)
Other 23 (9) 5 (10) 12 (11) 6 (7)
Mixed 18 (7) 10 (20) 5 (5) 3 (3)
Unknown 115 (46) 16 (32) 45 (42) 54 (59)
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would lead to predicted use of 3740 DDDs (95%
CI, 3594–3894), i.e., an increase of 21% (95% CI,
16–26%), while use of ATS guidelines would
increase antibiotic use to 4270 DDDs (95% CI,
4132–4399), i.e., an increase of 38% (95% CI, 33–
43%). The increase in antibiotic consumption
would be most apparent among patients with
moderate CAP (a 57% increase in antibiotic use
from 1229 to 1930 DDDs with BTS guidelines, a
57% increase to 1920 DDDs with IDSA guide-
lines, or a 66% increase to 2050 DDDs with ATS
guidelines; Fig. 1).
Calculated average drug costs per patient
treated, according to current practice, was 252
Euros; this would increase to 382 Euros with BTS
guidelines, 362 Euros with IDSA guidelines, and
475 Euros with ATS guidelines. For the present
cohort, the application of new British or North
American guidelines would lead to an estimated
increase in drug costs of 27 000–55 000 Euros.
With annual hospitalisations resulting from CAP
in The Netherlands of c. 16 000 [24], the estimated
annual increase in drug costs would be 1 750 000–
3 500 000 Euros.
Under current practice, 80 patients received
initial antibiotic therapy that covered atypical
pathogens. However, 71 (89%) of these patients
showed no evidence of infection with M. pneumo-
niae, C. pneumoniae or L. pneumophila. In contrast,
of the 21 patients with atypical infection, 12 (57%)
did not receive initial antibiotic treatment to cover
these pathogens.
DISCUSSION
The present study demonstrated that implementa-
tion of British or North American guidelines for
the treatment of CAP in The Netherlands would
result in a considerable increase in antibiotic use,
particularly in patients with moderate CAP being
treated in general hospital wards. This also
applies to countries with similar empirical treat-
ment strategies, such as the Nordic countries
[25,26]. The possible adverse consequences inc-
lude an increase in drug costs of >1 750 000 Euros
in TheNetherlands, an increase in side-effects, and
an increase in selective pressure that enhances the
development of antibiotic resistance.
Macrolide resistance in pneumococci has
already risen to 7% in The Netherlands (http://
www.earss.rivm.nl), and any further rise may
limit its use for empirical treatment. Bacterial
resistance to ﬂuoroquinolones is still low, but can
develop easily, even during treatment [20,27,28].
To justify an increase in antibiotic use, the
evidence must therefore be clear and convincing.
Thus, new treatment guidelines should either
lead to increased patient survival, or have better
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Fig. 1. Estimated antibiotic use (DDDs) for the treatment of community-acquired pneumonia in The Netherlands based on
current practice and guidelines of the British Thoracic Society (BTS), the Infectious Diseases Society of America (IDSA) and
the American Thoracic Society (ATS).
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cost-effectiveness. Increased patient survival has
not been demonstrated unequivocally; the new
recommendations for the use of b-lactam–macro-
lide combinations, or treatment with
ﬂuoroquinolones, are based on retrospective,
non-randomised studies, which only qualify as
level III evidence [29,30]. The ﬁrst of these studies
was published in 1999 [31]. Publication bias may
result in limited reporting of studies that fail to
demonstrate differences in outcome between
b-lactam monotherapy and combinations of
b-lactams and macrolides, or monotherapy with
ﬂuoroquinolones. Only two studies with negative
outcomes have been published [32,33]. In the
present study, infections with C. pneumoniae,
M. pneumoniae or L. pneumophila were infrequent,
and the clinical outcome for patients with evi-
dence of atypical infection who were not treated
with macrolides or ﬂuoroquinolones was favour-
able: thus, nine of 107 patients admitted to a
general ward with moderate CAP and atypical
infection were not treated for these microorgan-
isms, and all nine were discharged in good health
after a mean of 10.7 days.
The estimated cost increase may be even higher
in reality. In the cost estimates based on treatment
according to BTS guidelines, monotherapy was
assigned to patients in CURB classes 0 and 1.
However, BTS guidelines only recommend
monotherapy with a b-lactam if the patient has
not received therapy before admission, or is being
admitted for social reasons. Therefore, the total
number of DDDs that would be given under the
BTS guidelines may have been underestimated.
The contribution of atypical pathogens may vary
in different settings, but can be substantial
[7,16,34]. In addition, the diagnosis of atypical
infections by serological investigation is difﬁcult,
especially for C. pneumoniae [35]. If serological
evidence of C. pneumoniae indicates self-limiting
or previous infection, the number of untreated
atypical infections is lower. However, because of
the difﬁculties in diagnosing atypical infections, it
is possible that some patients with unknown
aetiology have had undetected atypical infections.
Treatment of these infections may increase the
cost-effectiveness of combinations of b-lactams
and macrolides.
Overestimation of the cost increase may also
have occurred because subjective clinical judge-
ment was not taken into account. Some patients
with one CURB point plus additional features
may have been classiﬁed as having non-severe
instead of severe pneumonia, and therefore
received a b-lactam plus a macrolide, instead of
ceftriaxone plus a macrolide. In addition, when
antimicrobial treatment is streamlined on the
basis of culture results, cost increases will be
smaller than calculated in the present study.
Current guidelines are based mainly on the
severity of presentation of CAP patients rather
than on the presumed causative pathogen. More
adequate initial treatment may be achieved by
using rapid diagnostic testing. For L. pneumo-
phila and S. pneumoniae, rapid urinary antigen
assays are available. The former is highly
speciﬁc and its use is now recommended for
all patients with severe CAP [16,36]. However,
the sensitivity of the S. pneumoniae assay is only
66–80%, which is probably insufﬁcient to guide
clinical care [37–40]. In the near future, rapid
diagnostic tests using real-time PCR will
become available, but their clinical value has
yet to be determined [41,42].
Although guidelines and critical pathways can
help in reducing the use of institutional resources
without adverse effects on the wellbeing of
patients [43], in practice, non-adherence to
national guidelines occurs frequently. Factors
contributing to non-adherence include the pres-
ence of active co-morbidities, the primary-care
physician’s decision concerning hospitalisation,
clinical interpretation, patient preference, or inad-
equate home support [44]. Consequently, clinical
judgement and social factors remain important in
making site-of-care and treatment decisions [45].
Furthermore, the effect on clinical outcomes of
adhering to guidelines has not been demonstra-
ted. In a recent study of 295 patients with CAP,
adherence to ATS guidelines was only associated
with a lower risk of mortality for severe CAP. For
the other risk classes, no signiﬁcant differences in
mortality or duration of hospital stay were found
[46]. Another study of 8975 patients with CAP
showed no effect on duration of hospital stay or
mortality for patients who were treated initially
for atypical pathogens, as recommended in North
American and British treatment guidelines, com-
pared with monotherapy with b-lactams [33].
In conclusion, the implementation of new
British or North American guidelines for the
treatment of CAP in The Netherlands is likely
to be associated with an increase in antibiotic
use. The clinical beneﬁt of these new strategies,
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however, still remains to be determined in rand-
omised trials.
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